USA - NASDAQ:NNNN - KYG0367B1059 - Common Stock
The current stock price of NNNN is 29.61 USD. In the past month the price decreased by -35.91%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.79 | 407.69B | ||
AMGN | AMGEN INC | 13.59 | 159.52B | ||
GILD | GILEAD SCIENCES INC | 15.1 | 145.06B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 106.60B | ||
REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.97B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.00B | ||
ARGX | ARGENX SE - ADR | 86.22 | 48.92B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.64 | 38.40B | ||
INSM | INSMED INC | N/A | 34.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.82B | ||
NTRA | NATERA INC | N/A | 23.68B | ||
BIIB | BIOGEN INC | 9.45 | 22.17B |
Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
ANBIO BIOTECHNOLOGY LTD
Friedrich-Ebert-Anlage 49
Frankfurt HESSEN DE
Employees: 27
Phone: 4916096247281
The current stock price of NNNN is 29.61 USD. The price increased by 0.51% in the last trading session.
The exchange symbol of ANBIO BIOTECHNOLOGY LTD is NNNN and it is listed on the Nasdaq exchange.
NNNN stock is listed on the Nasdaq exchange.
ANBIO BIOTECHNOLOGY LTD (NNNN) has a market capitalization of 1.30B USD. This makes NNNN a Small Cap stock.
ANBIO BIOTECHNOLOGY LTD (NNNN) currently has 27 employees.
ANBIO BIOTECHNOLOGY LTD (NNNN) has a support level at 25.94 and a resistance level at 34.13. Check the full technical report for a detailed analysis of NNNN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NNNN does not pay a dividend.
The PE ratio for ANBIO BIOTECHNOLOGY LTD (NNNN) is 740.25. This is based on the reported non-GAAP earnings per share of 0.04 and the current share price of 29.61 USD. Check the full fundamental report for a full analysis of the valuation metrics for NNNN.
The outstanding short interest for ANBIO BIOTECHNOLOGY LTD (NNNN) is 0.39% of its float. Check the ownership tab for more information on the NNNN short interest.
ChartMill assigns a fundamental rating of 6 / 10 to NNNN. NNNN gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months NNNN reported a non-GAAP Earnings per Share(EPS) of 0.04. The EPS increased by 57.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 46.57% | ||
ROA | 30.88% | ||
ROE | 31.77% | ||
Debt/Equity | 0 |